Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00908232 · BASELINE

Baseline characteristics

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD · Source last updated 2015-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      163
    units
    Participants
groups
  1. description
    bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for 4 cycles
    id
    BG000
    title
    All Study Participants
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.04
          value
          63.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          77
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          86
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      France
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      Germany
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          23
      title
      Greece
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Hungary
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      Lithuania
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          19
      title
      Poland
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      Serbia
    8. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      Spain
    9. categories
      1. measurements
        1. group Id
          BG000
          value
          19
      title
      Turkey
    10. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United Kingdom
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      163
    units
    Participants
groups
  1. description
    bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for 4 cycles
    id
    BG000
    title
    All Study Participants
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          11.04
          value
          63.7
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          77
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          86
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      France
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      Germany
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          23
      title
      Greece
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Hungary
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          9
      title
      Lithuania
    6. categories
      1. measurements
        1. group Id
          BG000
          value
          19
      title
      Poland
    7. categories
      1. measurements
        1. group Id
          BG000
          value
          15
      title
      Serbia
    8. categories
      1. measurements
        1. group Id
          BG000
          value
          20
      title
      Spain
    9. categories
      1. measurements
        1. group Id
          BG000
          value
          19
      title
      Turkey
    10. categories
      1. measurements
        1. group Id
          BG000
          value
          21
      title
      United Kingdom
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
population Description
modified Intent to Treat Population consisting of all 163 participants with at least 1 dose and 1 post baseline efficacy assessment.: Complete and Partial Responders (non-randomized), n=144. Stable Disease (randomized to VD, VDC, and VDL), n=19.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice